Cinryze
Alternative Names: C1 esterase inhibitor (human)
Cinryze is a C1 esterase inhibitor (C1-INH) replacement therapy used to prevent hereditary angioedema (HAE) attacks in adults, adolescents, and children. It works by supplying functional C1-INH protein to regulate the complement and contact systems, reducing the overproduction of bradykinin, which causes swelling. Cinryze is given by intravenous (IV) infusion, usually every 3 to 4 days as prophylaxis, not for acute attacks. It helps reduce the frequency and severity of HAE episodes, especially swelling of the skin, abdomen, or airway.
Treatment Type: Prescription Medication
Treatment Class: N/A
Treatment Modality: Intravenous (IV)
Review Summary
Based on the provided information, there are no user reviews available for the treatment 'Cinryze' against the disease 'Hereditary Angioedema'. Without any user feedback or author review, it is not possible to determine the effectiveness of this treatment from the given data.
This summary was generated by users' reviews
Breakdown by Category
Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.
Explore various treatment options to empower yourself in making a well-informed choice.
Choose treatments from the menu above to see how they compare side by side.
Choose treatments from the menu above to see how they compare side by side.
Choose treatments from the menu above to see how they compare side by side.
AI Summary of User Experiences
Not medical advice.
Based on the provided information, there are no user reviews available for the treatment 'Cinryze' against the disease 'Hereditary Angioedema'. Without any user feedback or author review, it is not possible to determine the effectiveness of this treatment from the given data.
Reviews
Filter by reviewer type Pro